Ibrance under the microscope: Real-World data on advanced breast cancer treatment

NCT ID NCT06962969

Completed Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study examined the safety and effectiveness of Ibrance (palbociclib) in women with advanced or metastatic breast cancer using a large real-world database. Researchers looked at side effects and how well the drug worked in everyday practice. The study included adult women with hormone receptor-positive, HER2-negative advanced breast cancer who had received at least one prescription of Ibrance.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ibrance (palbociclib)
What this could lead to: If successful, this study could confirm that Ibrance is safe and effective in everyday practice for women with advanced breast cancer.
What could go wrong: This is a very small study (only 1 participant) using existing database records, so results may not apply to all patients. It is observational, not a controlled trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED OR METASTATIC BREAST CANCER

Contacts and locations

Locations

Pfizer New York

New York, New York, 10001, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.